Jefferies Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $68
Jefferies analyst Akash Tewari initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Buy rating and announces Price Target of $68.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 5.4% to $2.73 during Wednesday's after-market session. The company's market cap stands at $35.2 million.
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 27)
Global Blood’s Sickle Cell Medicine Under FDA Review For Expanded Use
The FDA has accepted Global Blood Therapeutics Inc’s (GBT) (NASDAQ:GBT) supplemental application seeking accelerated approval for Oxbryta (voxelotor) for sickle cell…
Global Blood Therapeutics Announces FDA Has Accepted For Priority Review Supplemental New Drug Application For Oxbryta
New Drug Application for Oxbryta dispersible tablets also accepted for priority review
Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States
SOUTH SAN FRANCISCO, Sept. 07, 2021
Return on Capital Employed Insights for Global Blood Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $47.55 million. Despite a 7.22% in earnings, the company posted a loss of $65.91 million.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
